Cargando…
Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials
AIMS: Of patients with atrial fibrillation (AF), approximately 10% undergo percutaneous coronary intervention (PCI). We studied the safety and efficacy of dual vs. triple antithrombotic therapy (DAT vs. TAT) in this population. METHODS AND RESULTS: A systematic review and meta-analysis was conducted...
Autores principales: | Golwala, Harsh B, Cannon, Christopher P, Steg, Ph Gabriel, Doros, Gheorghe, Qamar, Arman, Ellis, Stephen G, Oldgren, Jonas, ten Berg, Jurrien M, Kimura, Takeshi, Hohnloser, Stefan H, Lip, Gregory Y H, Bhatt, Deepak L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951099/ https://www.ncbi.nlm.nih.gov/pubmed/29668889 http://dx.doi.org/10.1093/eurheartj/ehy162 |
Ejemplares similares
-
Design and Rationale of the RE‐DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting
por: Cannon, Christopher P., et al.
Publicado: (2016) -
The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE‐DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials)
por: Eccleston, David S., et al.
Publicado: (2021) -
Efficacy and safety of triple versus dual antithrombotic therapy in atrial fibrillation and ischemic heart disease: a systematic review and meta-analysis
por: Zhu, Wengen, et al.
Publicado: (2017) -
Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial
por: Nicolau, José C., et al.
Publicado: (2020) -
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial
por: Oldgren, Jonas, et al.
Publicado: (2019)